PSMA Development Company LLC (PDC), a joint venture of Progenics Pharmaceuticals, Inc. and Cytogen Corporation's findings of novel prostate cancer drug, prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) resulted positive. Dangshe Ma, Progenics' Senior Investigator, at the 12th Annual Prostate Cancer Foundation Scientific Retreat, reported the findings.
In a mouse model of human prostate cancer, PSMA ADC significantly prolonged overall survival up to nine-fold as compared to untreated animals. Remarkably, established tumors in two of the five animals treated at the highest dose were eradicated and remained undetectable over 500 days through the completion of the study. No overt evidence of toxicity was observed in any of these animal model tests, states a company release.
ADC drugs link a monoclonal antibody, which targets specific cells in the body, such as cancer cells, with a cell-killing payload.
Prostate cancer is the most common form of cancer affecting men in the United States and is the second leading cause of cancer deaths among men each year.
Progenics Pharmaceuticals Inc., of Tarrytown, NY is a biopharmaceutical company focusing on the development and commercialisation of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.